Zydus Wellness Q1 FY27: PAT down 7% YoY to ₹119 Cr as CCL costs squeeze margins
PAT -7.04% YoY · revenue +66.92% · margins compressing
₹1,437 Cr
+66.92% YoY
₹118.9 Cr
-7.04% YoY
8.25%
-6.6pp YoY
₹3.74
On a consolidated basis (primary), Zydus Wellness reported revenue of ₹1,437.0 Cr, up 66.9% YoY but down 3.2% QoQ, while PAT fell 7.0% YoY to ₹118.9 Cr and 26.6% QoQ from ₹162.0 Cr. The headline revenue jump is not organic growth — it reflects the full-quarter consolidation of Comfort Click Limited (CCL), acquired August 29, 2025, which the year-ago quarter did not carry at all. Notably, PBT actually rose 11.6% YoY to ₹162.1 Cr, so the entire PAT decline traces to items below the operating line.
Q1 FY-2027 vs prior quarters
NPM compressed to 8.3% from 14.8% YoY (10.9% QoQ) and OPM to 16.8% from 18.1% YoY (18.2% QoQ, using PBT-before-exceptionals less other income, plus finance cost and depreciation, over revenue — consistent with the margin convention in our records). The compression is driven by finance costs of ₹26.3 Cr (vs ₹2.5 Cr a year ago, a 10x jump) and depreciation/amortisation of ₹57.1 Cr (vs ₹10.8 Cr, ~5x) — both a direct consequence of CCL acquisition debt funding and PPA-related intangible amortisation. Separately, the effective tax rate rose sharply to 26.7% from 12.0% YoY, because a ₹4.6 Cr net MAT-credit-reversal benefit that lifted last year's quarter did not repeat this quarter (Note 6). Adjusting for that one-off tax item on a like-for-like basis, PAT would have been down only ~3.6% YoY rather than the reported 7.0% — meaning roughly half the headline PAT decline is a tax-benefit base effect, not a fresh operating deterioration, though margin compression from CCL financing/amortisation is real and structural for now.
The stock went into the print at ₹544.5, down 6.6% over the past month of trading.
What the summary numbers don't show
Consolidated EPS ₹3.74 for the quarter vs ₹5.09 in Q4FY26 and ₹4.02 in Q1FY26 (post-split-adjusted).
No exceptional items this quarter, versus ₹40.8 Cr of CCL-acquisition and NIPL-liquidation exceptional charges recorded across FY26.
Management expressed confidence in continued growth driven by innovation, portfolio scale-up, and margin expansion, leveraging data-driven and AI capabilities. While short-term headwinds for seasonal brands were noted due to weather, the company expects recovery. For the medium to long term, Zydus Wellness reiterates i
— This quarter: missed
No formal analyst consensus for this specific quarter was found in a web search, so vs-street is unknown. On guidance: the FY26-Q4 call reiterated a medium-to-long-term aspiration of 17-18% EBITDA margin and flagged short-term weather-related headwinds for seasonal brands with an expected recovery — this quarter's 16.8% OPM remains below that band, and revenue was down sequentially rather than showing the flagged recovery, a miss against that qualitative bar. No press release/MD&A accompanied this filing (management framing not extracted), but the filing's own Note 4 states Group revenue and profit are seasonally skewed toward Q1 and Q4 — despite Q1 being a stated peak quarter, PAT still fell 26.6% QoQ, mostly via costs/tax rather than topline (revenue was down just 3.2% QoQ). The standalone (India) business, a cleaner read on the base business, grew steadily: revenue ₹153.0 Cr (+8.6% YoY) and PAT ₹5.5 Cr (+19.6% YoY). Among this quarter's other developments, the company incorporated a new UAE subsidiary (June 30, 2026), continuing its Middle East footprint alongside existing Zydus Wellness General Trading DWC-LLC and Zydus Wellness Trading LLC entities, and its Head of Sales resigned (July 3, 2026) — a governance item worth tracking but with no numbers attached yet; a Polish subsidiary was fined PLN 54,000 for a tax filing delay, an immaterial amount.
W1
Whether finance costs and depreciation (₹26.3 Cr + ₹57.1 Cr this quarter, adding ~₹49 Cr of incremental cost YoY) moderate as CCL integration matures, given OPM of 16.8% still trails management's 17-18% EBITDA margin aspiration.
W2
Whether Q2 revenue confirms the recovery from weather-related seasonal-brand headwinds management flagged on the May 2026 call, after this quarter's sequential revenue dipped 3.2% despite being a stated peak season.
W3
Whether the MAT-credit-reversal tax benefit (absent this quarter, worth ₹4.6-21.8 Cr in the prior three quarters) recurs, which would materially aid reported PAT growth going forward.
The Profit That Wouldn't Follow the Growth
Revenue surged 67% to ₹1,437 crore, but net profit fell 7% to ₹119 crore. A massive restructuring — Comfort Click's ₹80–85 crore annual fixed cost — explains the gap. The real debate: can the company absorb that cost and still hit its 17–18% EBITDA margin target by FY28–29?
₹119 Cr
–7% YoY
~₹29 Cr
Comfort Click brands
~₹148 Cr
+26.5% YoY
On screen, Zydus delivered ₹1,437 crore in revenue and ₹119 crore in net profit. The headline is lopsided: while sales jumped 67% year-over-year, profit fell 7%. That gap — revenue booming while profit retreats — is the entire story of the quarter, and it is not a cash flow issue. It is a structural consolidation taking its toll on margins.
The Comfort Click tab
In Q4 FY26, Zydus acquired Comfort Click, a UK-based D2C health and wellness player. The company was consolidated into Zydus' P&L starting that quarter. In Q1 FY27, that consolidation is now full-quarter embedded. The tab: ₹80–85 crore in annual fixed costs (interest, depreciation, and amortization of acquired brands). Of that, roughly ₹24–30 crore flows through the P&L as amortization each quarter. That amortization is one reason reported PAT fell despite the massive revenue jump. Adjusted PAT — excluding amortization — rose 26.5% year-over-year, signalling the underlying cash generation is intact. But the amortization is real; it must be absorbed.
Consolidated net sales INR 14,370 million, 66.7% YoY growth
Verified: Revenue ₹1,437 Cr is 66.9% YoY growth
Supported
Net profit declined 7% YoY; adjusted PAT (ex-amortization) +26.5% YoY
Verified: Reported PAT ₹119 Cr (–7% YoY), adjusted ~₹148 Cr (+26.5% YoY)
Supported
EBITDA margin expansion 0.4% like-for-like basis; EBITDA growth 55.3%
Consistent with call data; margin expansion claim minimal but auditable
Supported (auditable)
Seasonal brands declined 12%, primarily softer summer rains East/North
Verified: Nycil and Glucon-D impacted by unseasonal monsoon April–May
Supported
Maintaining 17–18% EBITDA margin aspiration (long-term strategy)
Delivered OPM 16.8%, NPM 8.3%; timeline now described as 2–3 years, not near-term
Partially credible — aspiration held, timeline extended
What changed on this call
Comfort Click is now structural. ₹80–85 crore annual fixed cost embedded in the P&L; EPS accretive from Q4 FY26 onward, but margin accretion requires revenue scale. No easy de-lever if growth softens.
Domestic growth decelerated. Q1 domestic +4.6% vs. prior calls' implied double-digit trajectory. Seasonal brands down 12%; core brands (Complan, Everyuth, RiteBite) double-digit, but insufficient offset.
Margin expansion timeline extended. Aspiration to 17–18% EBITDA reiterated but now 'long-term' (2–3 years), not near-term. Prior calls' margin-expansion narrative downgraded.
Organized channel mix improved; seasonal risk acknowledged. Organized 38% (modern trade 17%, digital 21%); industry-leading. But portfolio volatility (–12% seasonal) shows diversification is incomplete.
The bull-bear ledger
Revenue growth 67% is structural (domestic +4.6%, international +24.8% like-for-like)
Premiumization working: Skin & Hair +34.5%, Food & Nutrition +16% growth
RiteBite >2× historical growth; Complan gaining despite category decline; Everyuth 5th→4th rank
Organized channel 38%, digital 21%; industry-leading mix supports margins long-term
Adjusted PAT +26.5% YoY shows underlying cash generation intact despite reported decline
Reported PAT –7% YoY despite 67% revenue growth signals 730bps margin compression
Fixed costs ₹80–85 Cr now permanent; fragile if growth slows or sentiment sours
Sequential QoQ deterioration severe: revenue –3.2%, PAT –26.6% (profit decline worse than sales)
Seasonal brands still volatile; Nycil/Glucon-D down 12%; 3-year shelf-life prolongs drag
Margin guidance credibility hit: aspiration held, but 2–3 year timeline extends inflection window
Risks, ranked by severity to a holder
Fixed-cost burden; margin inflection timing uncertain
HighComfort Click's ₹80–85 crore annual cost is now permanent overhead. If growth slows (domestic +4.6% is below trend), fixed-cost leverage inverts and margin compression accelerates. 17–18% EBITDA aspiration is 2–3 years out, not near-term.
Seasonal portfolio volatility unresolved
HighNycil/Glucon-D (East/North) down 12% this quarter; 3-year shelf-life means bad seasons prolong cash drain. Management expects monsoon recovery in Q2, but history shows seasonal brands structurally challenged. Channel inventory overhang risk remains.
Domestic growth deceleration
MediumQ1 domestic +4.6% materially below prior double-digit trajectory. Core brands growing double-digit (Complan, Everyuth, RiteBite), but offset insufficient. Premium mix helps, but core market momentum slower than guided.
Earnings quality and amortization dependency
MediumReported vs. adjusted PAT gap of ~₹29 crore creates large narrative window. Amortization (~₹24–30 crore quarterly) will persist for years. Tempts management to emphasize adjusted metrics and obscure core profitability strain.
The street's view
The stock fell 3.6% on day 1 post-result and declined 2.85% by day 3, holding the loss with no recovery pop. The market's verdict: disappointing, but not catastrophic. At ₹534.5, the stock trades 12.46% below its all-time high of ₹610.6 but sits 45.42% above its 52-week low (₹367.55). Price action sits below both the 20-day and 50-day moving averages (₹567.59 and ₹546.55) but above the 200-day (₹473.08), signalling intermediate weakness without structural breakdown. RSI at 31.5 is neutral — not oversold. Institutions aren't fleeing: FII ownership ticked up from 3.18% to 3.32%; DII held stable at ~19%; promoter remains firm at 69.64%, unchanged for three years. Volume has increased, confirming the move is not low-volume. The market is repricing from 'growth at any cost' to 'growth with profitability questions' — fair, given sequential PAT decline and margin guidance credibility hit.
1 · Q2 organic run-rate (monsoon recovery, seasonal rebound)
Is the seasonal drag truly temporary, or does it prolong into Q2? Nycil/Glucon-D (East/North) recovery timing will define whether the 12% decline was a one-quarter trough or the start of prolonged headwind. Management expects recovery 'towards the end of Q1' and into Q2; numbers will confirm or refute. Watch for QoQ PAT inflection.
2 · Comfort Click ramp velocity (U.S./Middle East expansion, unit economics)
Comfort Click like-for-like growth was +24.8% in established markets (Europe). U.S. entry (WeightWorld D2C, Walmart, noon UAE) is 'very small, early stage, growing well.' Next quarter shows whether U.S./Middle East expansion is tracking to scale or remains niche. Margin inflection case depends on this business reaching ₹500+ crore revenue over 2–3 years.
3 · RiteBite offline T2/T3 expansion and EBITDA contribution
RiteBite >2× historical growth driven heavily by quick commerce. Offline expansion into T2/T3 towns is underway with committed resources. If that scales, RiteBite becomes a meaningful profit driver and validates premiumization thesis. Watch for quick commerce saturation and general trade traction.
This quarter is a test of whether growth and profitability can coexist at Zydus Wellness. Reported numbers suggest they cannot — not yet. But the adjusted figures suggest the business remains fundamentally sound; Comfort Click is a temporary profit headwind, not a strategy error. The honest read is steady execution, not a step-change. Revenue growth is structural; margin inflection is multi-year and contingent on Comfort Click scale and domestic growth recovery. The number to track from here is the organic profit run-rate (adjusted PAT) and the pace of Comfort Click revenue ramp. If domestic growth stays below 5% and Comfort Click remains a single-digit revenue contributor, the 17–18% EBITDA margin target will remain a 3-year aspiration. The street has priced in skepticism. Execution will decide whether that view holds.
Strong growth masked by sharp profit decline and margin compression
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Hit FY27 revenue guidance (67% growth on prior expectation of double-digit), but missed profit target—PAT declined 7% despite 67% revenue, suggesting margin pressure vs. prior calls.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue growth of 67% is structural and credible (mix: domestic +4.6%, international +24.8%), but profit declined 7% YoY and 26.6% sequentially, signaling margin compression. The key risk: even with Comfort Click accretion and premiumization, achieving the 17-18% EBITDA margin aspiration requires significant near-term inflection. Weather-driven seasonal drag (Nycil -12%) is temporary, but consolidated fixed costs and amortization will persist.
₹1437 Cr
Revenue · +66.9% YoY₹118.9 Cr
Reported PAT · −7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Consolidated net sales INR 14,299 million, 66.7% YoY growth
METRevenue 1437 Cr = 14,370 million, actual 66.9% YoY growth
Net profit declined 7% during quarter
METPAT -7.0% YoY per delivered results
EBITDA growth 55.3%, EBITDA margin expansion 0.4% like-to-like basis
MixedNo absolute EBITDA provided; claim of margin expansion unsupported by delivered NPM of 8.3%
Seasonal brands declined 12% primarily due to softer summer
METConsistent with geographic and brand-level commentary on Nycil/GluconD
Domestic business grew 4.6%, International 24.8% like-for-like
UnverifiedNot independently verifiable from delivered results; claims specific but not audited
Earnings quality
What changed since the last call
Comfort Click consolidated into P&L
NewQ1: ₹80-85Cr annual fixed cost (interest + depreciation) now embedded. Structural change driving profit dilution despite revenue growth. EPS accretive from Q4 FY26 onward; margin accretion expected as revenue scales.
Domestic growth decelerated materially
DowngradeQ1 FY27 domestic +4.6% vs. prior call expectations of stronger momentum. Seasonal brands down 12%, though core brands (Complan, Everyuth, RiteBite) growing double-digit. Prior guidance implied steadier domestic trajectory.
Margin expansion timeline pushed out
DowngradeAspiration 17-18% EBITDA margins maintained, but OPM 16.8%, NPM 8.3% suggest multi-year lag. Prior calls hinted margin expansion imminent via premiumization; now emphasized 'long-term' pipeline (2-3 years).
Channel mix improved, seasonal dependency acknowledged
NeutralOrganized channel 38% (modern trade 17%, digital 21%), industry-leading. But diversification narrative undermined by -12% seasonal portfolio decline; portfolio still exposed.
International growth guidance maintained but vague
Neutral24.8% like-for-like this quarter; management restates 'double-digit' aspiration but declined to guide specific growth rate. Comfort Click U.S. entry described as 'very small, growing well'—early stage, not a near-term driver.
The Q&A
Analysts pressed on seasonal portfolio channel risks (inventory overhang, rollover), margin expansion capability despite high fixed costs, and geographic performance detail. Management held firm on growth narrative (all brands ex-seasonal in double-digit growth) but got defensive on profitability (deflected on multi-year mix projections, inventory visibility). Moderate pressure; management credibility slightly strained by profit miss.
International growth constraints — Hardik Jatheliya, Ardeko Asset Management
AnsweredNo specific constraints. 25% is solid, in line with double-digit guidance we maintain going forward.
Tax & interest costs — Simran Kumari, Narnolia Financial Services
AnsweredQ1 ETR 27% (thin cap rule impact); normalizes to 25% with 12-15% cash component FY27, 25% all-cash FY28. GBP→Euro reduced interest cost; Euro base rate now benchmark, similar run-rate ahead. RiteBite >2x historical growth, driven by brand building, distribution expansion, portfolio enhancement.
Seasonal portfolio geographic breakdown — Umang Shah, Banyan Tree Advisors
AnsweredGlucon-D: East took biggest hit (continued rains April-May), North/West/South positive. Nycil: North/East (key saliency markets) heavily impacted, West/South grew double-digit. High retail inventory also depressed offtakes. Second half quarter showed recovery; momentum returning.
Comfort Click EBITDA sustainability — Mayur Parkeria, Wealth Managers India
AnsweredEPS accretive from Q4 FY26 onward, will continue. If momentum sustains, net margin and EBITDA will increase even in seasonal quarters.
Comfort Click GLP-1 tailwind — Mayur Parkeria, Wealth Managers India
PartialAll products OTC, digital-only, no doctor prescription. U.S. entry very small, early stage, growing per expectations. Too early to predict scale, but we're building and positive.
Seasonal inventory rollover risk — Ronak Shah, Equirus Securities
PartialHard to predict beyond visibility. Own inventory lower than last year. Products have 3-year shelf life, so bad seasons can prolong usage. Consumers buy 1-1.5 packs/season. Already seeing positive growth momentum in recent months. Numbers will play out.
RiteBite offline expansion — Ronak Shah, Equirus Securities
AnsweredStrong traction, committed resources. Deeper and wider expansion underway. Selective approach—high-value products, top towns still main throughput. Next two class of towns showing good traction. Rural too far for now.
Comfort Click geography split — Ronak Shah, Equirus Securities
DodgedDon't segregate U.K. vs. rest of Europe. Europe has five key markets (U.K., France, Italy, Germany, Spain) forming bulk of business. Overall growth rate captured here. Won't share market-by-market detail.
Complan turnaround drivers — Aniket Kamble, ICICI Securities
AnsweredConsistent approach: segmented Complan into 3-4 segments (core kids, toddler NutriGro, adult VieMax/VieMax Diabetes, RTD Powerplay). Investment in advertising, celebrity (Vaibhav Sooryavanshi), distribution expansion. Multiple formats driving acceptance. Kids nutrition is core driver.
Protein portfolio mix evolution — Parth Sodha, Trinetra Asset Managers
PartialEach category has substantially large possibilities. Driving each with equal conviction. Bars largest today; hard to predict 3 years out.
Everyuth adjacent expansion — Parth Sodha, Trinetra Asset Managers
AnsweredCore facial cleansing has enough room to grow (scrubs, peel off, face wash). Exploring tan removal, anti-pollution in pipeline. Beyond that, selective exploration (resource constraints). Piloting other spaces. Priority on facial cleansing scalability.
RiteBite acquisition & SKU expansion — Mayur Parkeria, Wealth Managers India
AnsweredOriginal products still core drivers. Expanded into newer spaces: wafer bar (millet-based), Roots (ghee/jaggery/dates), Korean chips, RTDs, Max Protein cookies. Each platform sizable. Original + expanded portfolios driving growth; reaching new consumers.
Everyuth B2B expansion — Mayur Parkeria, Wealth Managers India
AnsweredNo. Focused on B2C for now.
A&C spend and digital shift — Aniket Kamble, ICICI Securities
AnsweredA&C 18.2% of sales overall (includes Comfort Click, which has higher %). Like-for-like, similar to prior year on core. Digital spend % rising due to consumer media consumption shift; engagements sharper on digital. Spends pivoting to digital.
Guidance
Domestic double-digit growth aspiration (historical); international double-digit (stated this call)
MediumInternational 24.8% this quarter (above stated double-digit). Domestic 4.6% (below). Mix: seasonal drag temporary, core brands on track.
17-18% EBITDA margin aspiration; 'long-term growth strategy'
LowDelivered OPM 16.8%, NPM 8.3% vs. aspiration. No specific FY27 target; described as multi-year (2-3 years) objective. Comfort Click accretion, premiumization expected to support.
No explicit capex target provided; focus on 'disciplined execution, technology-enabled decision-making'
MediumDistribution expansion commitment (RiteBite T2/T3, quick commerce). Comfort Click U.S./Middle East buildout ongoing. No capex quantum disclosed.
Risks the call surfaced
Seasonal portfolio dependency
HighNycil/GluconD East declined due to unseasonal rains; 12% seasonal portfolio decline. Shelf-life (3 years) prolongs bad-season impact. Recovery dependent on monsoon exit.
Margin compression vs. guidance
HighRevenue +67% YoY but PAT -7%, suggesting 730bps margin compression. OPM 16.8%, NPM 8.3% vs. 17-18% EBITDA aspiration. Comfort Click amortization ₹24-30Cr masks core profit recovery.
Sequential deterioration unresolved
HighQoQ revenue -3.2%, PAT -26.6%. Sequential decline worse than seasonal headwind alone. Suggests fixed-cost deleverage, working capital timing, or demand cliff.
Comfort Click integration risk
MediumConsolidated ₹80-85Cr annual fixed cost (interest + depreciation). Amortization of acquired brands ₹24-30Cr embedded, depressing reported PAT. If revenue growth softens, leverage inverts.
Domestic growth deceleration
MediumDomestic +4.6% YoY, well below historical double-digit expectation. Offset by international growth and premiumization, but core business momentum slower than guided.
Management
Score 7/10. Clear on operational metrics (brand growth, channel saliency, geographic breakdowns). Selective on forward guidance (avoids market-by-market splits, multi-year revenue projections). Transparent on seasonal headwinds and input costs. Some defensive language on profitability. Hit revenue growth targets (67% vs. prior double-digit guidance). Missed profit delivery (PAT -7% YoY when margins expected to expand). RiteBite and Everyuth brand momentum strong. Seasonal portfolio weakness prolonged (not yet recovered). Comfort Click consolidation on track but margin uplift timing delayed.
1 · Q2 FY27
Weather recovery lifts seasonal brands; monsoon eases demand pressure on Nycil, GluconD
2 · H2 FY27
Summer season returns; channel inventory correction clears; seasonal portfolio rebounds
3 · Ongoing
RiteBite Max Protein offline expansion into T2/T3; distribution depth/width commitment
Weather-driven seasonal drag (Nycil -12%) is temporary, but consolidated fixed costs and amortization will persist.